As of 2026, the global pharmaceutical landscape has witnessed a significant pivot toward selective kinase inhibition. The Jak3 (Janus Kinase 3) Inhibitor Market a vital subset of the broader JAK inhibitor family, is at the forefront of this shift. Unlike JAK1 and JAK2, which are expressed across various tissues, JAK3 is primarily found in hematopoietic and immune cells, making it a "p...